Quiet NeuroPhage nabs $12.4M in Series B round
Cambridge-based NeuroPhage Pharmaceuticals Inc. has landed $12.4 million in a Series B round of funding led by MerieuxDeveloppement, the investment arm of French industrial holding company InstitutMerieux, with Shire LLC as a new investor and participation from existing investors.
This latest funding brings the total raise by NeuroPhage to $19.6 million since it launched in December of 2006, based on intellectual property licensed from professor Beka Solomon’s laboratory at Tel Aviv University. The company is led by co-founder Jonathan Solomon, a former Medtronic executive, who serves as president and CEO, according to the NeuroPhage website. Biogen Idec Inc. veteran Richard Fisher serves as chief scientific officer.